Search Results - "Flaherty, Keith"

Mechanisms of resistance to immune checkpoint inhibitors by Jenkins, Russell W, Barbie, David A, Flaherty, Keith T

“…Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are…”
Get full text

A twenty year perspective on melanoma therapy by Flaherty, Keith T.

“…Melanoma had long been considered to be particularly addressable with immunotherapy, but that reputation was built on modestly effective cytokine‐based…”
Get full text

Vemurafenib by Flaherty, Keith. T, Yasothan, Uma, Kirkpatrick, Peter

“…In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the…”
Get full text

Targeted agents and immunotherapies: optimizing outcomes in melanoma by Luke, Jason J., Flaherty, Keith T., Ribas, Antoni, Long, Georgina V.

“…Key Points Clinical therapeutics for advanced-stage melanoma have improved dramatically with the development of BRAF and MEK inhibitors, cytotoxic…”
Get full text

Precision medicine for cancer with next-generation functional diagnostics by Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.

“…Genome-based cancer therapeutic matching is limited by incomplete biological understanding of the relationship between phenotype and cancer genotype. This…”
Get full text

Resistance to BRAF-targeted therapy in melanoma by Sullivan, Ryan J., Flaherty, Keith T.

“…BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or…”
Get full text

The rise of new targets in melanoma by Bai, Xue, Flaherty, Keith T

“…Despite advancements in cancer treatment, the clinical options remain limited and therapeutic resistance inevitably develops. In melanoma, the second most…”
Get full text

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma by Dummer, Reinhard, Long, Georgina V, Robert, Caroline, Tawbi, Hussein A, Flaherty, Keith T, Ascierto, Paolo A, Nathan, Paul D, Rutkowski, Piotr, Leonov, Oleg, Dutriaux, Caroline, Mandalà, Mario, Lorigan, Paul, Ferrucci, Pier Francesco, Grob, Jean Jacques, Meyer, Nicolas, Gogas, Helen, Stroyakovskiy, Daniil, Arance, Ana, Brase, Jan C, Green, Steven, Haas, Tomas, Masood, Aisha, Gasal, Eduard, Ribas, Antoni, Schadendorf, Dirk

“…Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity…”
Get more information

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways by Bai, Xue, Fisher, David E, Flaherty, Keith T

“…Targeted therapy and immunotherapy have greatly improved the prognosis of patients with metastatic melanoma, but resistance to these therapeutic modalities…”
Get full text

BRAF targeted therapy changes the treatment paradigm in melanoma by Ribas, Antoni, Flaherty, Keith T.

“…Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target. The authors describe the scientific…”
Get full text

The Conundrum of Genetic "Drivers" in Benign Conditions by Kato, Shumei, Lippman, Scott M, Flaherty, Keith T, Kurzrock, Razelle

“…Advances in deep genomic sequencing have identified a spectrum of cancer-specific passenger and driver aberrations. Clones with driver anomalies are believed…”
Get more information

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial by Davies, Michael A, Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Flaherty, Keith T, Arance, Ana, Chiarion-Sileni, Vanna, Thomas, Luc, Lesimple, Thierry, Mortier, Laurent, Moschos, Stergios J, Hogg, David, Márquez-Rodas, Iván, Del Vecchio, Michele, Lebbé, Céleste, Meyer, Nicolas, Zhang, Ying, Huang, Yingjie, Mookerjee, Bijoyesh, Long, Georgina V

“…Dabrafenib plus trametinib improves clinical outcomes in BRAFV600-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus…”
Get full text

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth by Kleffel, Sonja, Posch, Christian, Barthel, Steven R, Mueller, Hansgeorg, Schlapbach, Christoph, Guenova, Emmanuella, Elco, Christopher P, Lee, Nayoung, Juneja, Vikram R, Zhan, Qian, Lian, Christine G, Thomi, Rahel, Hoetzenecker, Wolfram, Cozzio, Antonio, Dummer, Reinhard, Mihm, Jr, Martin C, Flaherty, Keith T, Frank, Markus H, Murphy, George F, Sharpe, Arlene H, Kupper, Thomas S, Schatton, Tobias

“…Therapeutic antibodies targeting programmed cell death 1 (PD-1) activate tumor-specific immunity and have shown remarkable efficacy in the treatment of…”
Get more information

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine by Geller, Leore T, Barzily-Rokni, Michal, Danino, Tal, Jonas, Oliver H, Shental, Noam, Nejman, Deborah, Gavert, Nancy, Zwang, Yaara, Cooper, Zachary A, Shee, Kevin, Thaiss, Christoph A, Reuben, Alexandre, Livny, Jonathan, Avraham, Roi, Frederick, Dennie T, Ligorio, Matteo, Chatman, Kelly, Johnston, Stephen E, Mosher, Carrie M, Brandis, Alexander, Fuks, Garold, Gurbatri, Candice, Gopalakrishnan, Vancheswaran, Kim, Michael, Hurd, Mark W, Katz, Matthew, Fleming, Jason, Maitra, Anirban, Smith, David A, Skalak, Matt, Bu, Jeffrey, Michaud, Monia, Trauger, Sunia A, Barshack, Iris, Golan, Talia, Sandbank, Judith, Flaherty, Keith T, Mandinova, Anna, Garrett, Wendy S, Thayer, Sarah P, Ferrone, Cristina R, Huttenhower, Curtis, Bhatia, Sangeeta N, Gevers, Dirk, Wargo, Jennifer A, Golub, Todd R, Straussman, Ravid

“…Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize…”
Get more information

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis by McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew, Lane, Stephen, Lee, Dung-Yang, Kaper, Mathilde, McKean, Meredith, Beckermann, Kathryn E, Rubinstein, Samuel M, Rooney, Isabelle, Musib, Luna, Budha, Nageshwar, Hsu, Jessie, Nowicki, Theodore S, Avila, Alexandre, Haas, Tomas, Puligandla, Maneka, Lee, Sandra, Fang, Shenying, Wargo, Jennifer A, Gershenwald, Jeffrey E, Lee, Jeffrey E, Hwu, Patrick, Chapman, Paul B, Sosman, Jeffrey A, Schadendorf, Dirk, Grob, Jean-Jacques, Flaherty, Keith T, Walker, Dana, Yan, Yibing, McKenna, Edward, Legos, Jeffrey J, Carlino, Matteo S, Ribas, Antoni, Kirkwood, John M, Long, Georgina V, Johnson, Douglas B, Menzies, Alexander M, Davies, Michael A

“…Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is…”
Get full text

Toward Minimal Residual Disease-Directed Therapy in Melanoma by Rambow, Florian, Rogiers, Aljosja, Marin-Bejar, Oskar, Aibar, Sara, Femel, Julia, Dewaele, Michael, Karras, Panagiotis, Brown, Daniel, Chang, Young Hwan, Debiec-Rychter, Maria, Adriaens, Carmen, Radaelli, Enrico, Wolter, Pascal, Bechter, Oliver, Dummer, Reinhard, Levesque, Mitchell, Piris, Adriano, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, van den Oord, Joost, Voet, Thierry, Aerts, Stein, Lund, Amanda W, Marine, Jean-Christophe

“…Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results…”
Get more information

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials by Long, Georgina V, Grob, Jean-Jacques, Nathan, Paul, Ribas, Antoni, Robert, Caroline, Schadendorf, Dirk, Lane, Stephen R, Mak, Carmen, Legenne, Philippe, Flaherty, Keith T, Davies, Michael A

“…Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAFV600E-mutant or BRAFV600K-mutant…”
Get full text

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy by Smith, Michael P, Brunton, Holly, Rowling, Emily J, Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L, Girotti, Maria R, Marais, Richard, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Flaherty, Keith T, Cooper, Zachary A, Wargo, Jennifer A, Wellbrock, Claudia

“…Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major…”
Get more information

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations by Voss, Martin H, Hierro, Cinta, Heist, Rebecca S, Cleary, James M, Meric-Bernstam, Funda, Tabernero, Josep, Janku, Filip, Gandhi, Leena, Iafrate, A John, Borger, Darrell R, Ishii, Nobuya, Hu, Youyou, Kirpicheva, Yulia, Nicolas-Metral, Valerie, Pokorska-Bocci, Anna, Vaslin Chessex, Anne, Zanna, Claudio, Flaherty, Keith T, Baselga, Jose

“…To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor. This was a first-in-human, multicenter,…”
Get more information

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma by Dummer, Reinhard, Flaherty, Keith T, Robert, Caroline, Arance, Ana, de Groot, Jan Willem B, Garbe, Claus, Gogas, Helen J, Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, di Pietro, Alessandra, Cantey-Kiser, Jean, Edwards, Michelle, Ascierto, Paolo A

“…Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of…”
Get more information